A Study of Novel Treatment Combinations in Patients With Lung Cancer
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this platform clinical trial is to test novel treatment combinations in
participants with lung cancer. The platform study will consist of 2 initial substudies. New
substudies and/or treatment arms may be added to the study through amendment of the master
protocol and/or substudy protocols.
Two initial substudies will enroll in parallel:
The goal of Substudy-01 is to see if different combinations of experimental drugs named
zimberelimab, domvanalimab, sacituzumab govitecan and etrumadenant are safe and effective for
persons with no prior systemic treatment as compared to standard of care.
The goal of Substudy-02 is to see if different combinations of experimental drugs named
zimberelimab, sacituzumab govitecan, etrumadenant are safe and effective for persons whose
cancer has progressed after receiving previous treatment for metastatic NSCLC (form of cancer
that can spread from one part of body to another). The safety and effectiveness will be
compared to standard of care.